News, views and contacts from the global Pharmaceutical industry
26 June 2017
Digital Magazine
Latest Companies

Lablabo - Airless Metering Pumps for the Pharmaceutical Industry

Labworks International Inc. - Environment Controlled Rooms, Cleanrooms, ICH Stability Chambers, Freezers, and Coolers for Temperature-Sensitive Pharmaceutical and Medical Products

Reliability and Maintenance Services Ltd - ISO17025 Accredited Calibration Services for Temperature, Humidity, and Pressure Instrumentation

tricumed Medizintechnik - Implantable Infusion Pumps to Treat Spasticity and Chronic Pain

Delta 2000 - Architectural Solutions for Cleanrooms

Pharmaceutical Technology on Facebook

Join Pharmaceutical Technology on Facebook!
We're on Facebook and we'd like you to join us there too. Now there's a new way to keep up on our biggest stories, breaking news and exclusive content. Become a fan of Pharmaceutical Technology on Facebook and click the 'like' button. Simple as that!

Press Releases

Getting Up to Date with Complex Generics
Are you up-to-date on complex generics? You probably already know they are inherently difficult to duplicate, yet still reviewed by CDER-OGD (not CBER) using 505(j) Abbreviated New Drug Applications (ANDAs).

Freighter Capacity At Your Doorstep
Air Canada Cargo's dedicated freighter service provides year-round main and lower deck capacity for your shipments to key markets including Toronto, Atlanta, Dallas-Fort Worth, Mexico City, Bogota, Lima, and Frankfurt.

HOF Sonderanlagenbau's Control and Visualisation Systems Offer process-Oriented Operation
A rise in requirements for freeze-drying documentation and processes is consistently a challenge for system control.

Specialised Pharmaceutical Vibrating Separators
Russell Finex's customised vibrating separator The Finex Separator™ has helped a pharmaceutical filler manufacturer of newly developed powder oxygen therapeutic (OC) increase productivity and product quality.

PBL Gains Approval to Advance Next Generation Anthrax Vaccine
Porton Biopharma Ltd (PBL) has announced that it has signed a modification to its contract with the US National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vaccine. The contract modification is worth US$5.6 million.

White Papers

Sequential Sterilization of Simple Effluent Biowaste Streams
The AutoFlow SINK was designed for small laboratory applications such as research, virology, vaccines, and genetically modified organisms (GMO) in contract research organisations (CMO),...

Application Case Study: Parallel Process Development and Scale-Up by Factor 300
In this case study, three reactor systems (FlexyCUBE 70ml, FlexyPAT 2l, and ChemTeacktor 25l) are operated on the same PC using application software FlexySys....

Dehumidified Air Ensures Quality Hormone Packaging for Orion Pharmaceuticals
Production of hormone medication involves packing in foil blister packs. The process includes cooling and requires very cold machine...

Testing Parenteral Products for Micro Leaks, Container Closure Integrity Test
The E-Scan 655 tests container closure integrity in syringes, vials, and other liquid-filled parenteral...

Child Safe Packaging Today
As physicians become more reliant on prescribing medications to treat illness instead of advocating preventive measures, risks associated with accidental medication poisoning is...


Pharma Technology Focus – Issue 60
In this issue: Solving US drug pricing issues by importing cheaper Canadian drugs, underexplored fields in immuno-oncology, a new temperature-resistant rabies and yellow fever vaccine, the increasingly popularity of adaptive clinical trials, and more.

Counting the cost of failure in drug development
Most people who have a passing association with the pharmaceutical business will be able to give a rough estimate of how much it costs to take a drug candidate through clinical trials and regulatory approval. The estimate would likely be based on something like the Tufts Center for the Study of Drug Development’s (CSDD) regular assessment of drug development costs, which states the average cost of reaching marketing approval at just under $2.6bn.

Could a temperature-resistant vaccine spell the end for rabies and yellow fever?
Rabies and yellow fever claim tens of thousands of lives every year. Although vaccines do exist, they are either expensive or in short supply. In addition, they need to be transported and stored at controlled temperatures. A consortium led by KU Leuven aims to tackle all of these issues by developing a cheap, temperature-stable, and easy-to-produce vaccine against both diseases simultaneously.

May's top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken
Thermo Fisher Scientific agreed to acquire Dutch contract development and manufacturing organisation (CDMO) Patheon for $7.2bn. AstraZeneca entered an agreement to provide the commercial rights for Seloken / Seloken ZOK and associated Logimax fixed-dose combination treatments in Europe to Recordati. Pharmaceutical-technology.com wraps up the key headlines from May.

Pooling resources for clinical trials
Adaptive clinical trial models, which allow researchers to tweak and change a trial as it progresses, are becoming more and more popular. But are pharma companies willing to make the changes to both infrastructure and mind-set to allow for more flexible protocols? Abi Millar finds out.


Experimental Sciences Building II (ESB II), Texas Tech University
Texas Tech University along with Texas Tech University System started the construction of the new Experimental Sciences Building II (ESB-II) at the Lubbock campus in Texas, US, in February 2017.

Boehringer Ingelheim China Biopharmaceuticals Project, Shanghai
Boehringer Ingelheim is developing a biologics manufacturing facility in Zhang Jiang Hi-tech Park, Shanghai.

AGORA Cancer Centre, Lausanne
AGORA cancer centre is being constructed at the Lausanne hospital site, adjacent to the Lake of Geneva, Switzerland.

European Molecular Biology Laboratory Site, Barcelona
European Molecular Biology Laboratory (EMBL) is developing a new facility within the Barcelona Biomedical Research Park (PRBB) campus in Spain.

AstraZeneca R&D Centre and Corporate Headquarters, Cambridge
UK-Swedish pharmaceutical and biologics company AstraZeneca is building a new global R&D centre and corporate headquarters on the Cambridge Biomedical Campus (CBC) in Cambridge, UK.

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Pharmaceutical Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.pharmaceutical-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.